Register for our free email digests:
MGI PHARMA
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MGI PHARMA
Eisai Joins PROTAC Club Through New Oncology Collab
Japanese firm joins increasing global interest in PROTAC approach to cancer as it links with UK university for drug discovery collaboration.
Eisai's New Venture Fund Looks To ‘Excavate’ Innovation
Japanese pharma firm’s new venture capital fund aims to support and gain access to external innovation both at home and in the US, while a new alliance with a Japanese tech services firm will pursue opportunities in digital health and dementia.
Sale of Invention May Block Its Patenting Even If Details Are Not Disclosed, Supreme Court Concludes
America Invents Act did not alter the meaning of "on sale," unanimous court finds, so a confidential sale can qualify as prior art.
Brand Vs. Generic Supreme Court Fight: Does Sale Of Secret Invention Bar Its Patenting?
In case with potentially broad ramifications for biopharma partnerships, high court will hear arguments Dec. 4 on whether America Invents Act changed the "on-sale bar" to patentability to allow inventions that are sold to be patented if their details are not publicly disclosed.